Scott Kono, DO, MS

Publications

• Switching from Biologic to Biosimilar Products: Insight from an Integrated Health Care System BioDrugs volume 36, pages 1–11 (2022)
• Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I JCO Precis Oncol, 2022 Feb;6:e2100424 PMID 35138919
• Krop IE, Jegede OA, Grilley-Olson JE, Lauring JD, Mitchell EP, Zwiebel JA, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Kono SA, Ford JM, Garcia AA, Sui XD, Siegel RD, Slomovitz BM, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. JCO Precis Oncol. 2022 Feb;6:e2100424. PubMed PMID: 35138919
• Bhardwaja B, Klocke S, Ekinci E, Jackson A, Kono S, Olson KL. Switching from Biologic to Biosimilar Products: Insight from an Integrated Health Care System. BioDrugs. 2022 Jan;36(1):1-11. PubMed PMID: 34817847

Practice Locations

Hospital Affiliation

• University of Colorado Hospital

Specialty Information

Specialties

• Medical Oncology, Board Certification